Sonnet biotherapeutics announces webcast to discuss clinical data from the sb101 study with son-1010 being presented at the aacr 2023 annual meeting

Princeton, nj / accesswire / april 17, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share data from its sb101 clinical study with son-1010 in oncology patients (nct05352750) on tuesday, april 18, 2023 at 5:00 pm et. webcast presenters will include: richard kenney, m.d.
SONN Ratings Summary
SONN Quant Ranking